A large study led by the Karolinska Institute in Sweden shows that artificial intelligence can be used to accurately diagnose and grade prostate cancer in a way that is generalizable across different populations.
Cancer Research UK’s Centre for Drug Development will sponsor and manage the trial and Roche will provide the first five targeted therapies for evaluation.
Central to the deal was GeneDx’s rare disease diagnosis and clinical exome sequencing capabilities along with data from more than 300,000 exomes and 2.1 million annotated patient phenotypes.
Large-scale study strengthens link between Epstein-Barr Virus (EBV) infection and multiple sclerosis (MS). Prior EBV infection raises risk of MS 32-fold.
New findings suggest engineered DNA-free virus-like particles are an attractive alternative to other delivery strategies for the in vivo or ex vivo delivery of base editors, nucleases, and other proteins of therapeutic interest.
Of note in the recently released updated guidance, was information on the use of a human monoclonal antibody treatment regimen as a preventive measure against contracting COVID-19.
A combination of splice-switching antisense oligonucleotides could work against a common CFTR mutation that causes a severe form of cystic fibrosis, according to new research.
The four-marker protein panel (4MP) includes four proteins—the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment—that have previously shown potential to identify people at risk of developing lung cancer.
Cancer diagnostics company Exact Sciences has acquired PreventionGenetics and entered an exclusive license agreement for OncXerna’s Xerna TME Panel Lab to support its entrance into the field of hereditary cancer testing and cancer prognosis prediction.
Through research done mostly in a mouse model, Canadian scientists have identified a biomarker, soluble E-selectin, that could be used to test whether women, but not men, have neurovascular signs of depression.